{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:14Z","timestamp":1788966074741,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":3581,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T00:00:00Z","timestamp":1459382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Loop diuretics are first-line medications for congestive heart failure (CHF); however, they are associated with serious adverse effects, including decreased renal function, and sympathetic nervous and renin\u2013angiotensin system activation. We tested whether tolvaptan, a vasopressin V2-receptor antagonist, could reduce unfavourable furosemide-induced effects during CHF treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Sixty patients emergently hospitalized owing to CHF-induced dyspnea were randomly assigned to receive either 40 mg intravenous furosemide daily or 7.5 mg oral tolvaptan for 5 days after admission. Both groups also received intravenous carperitide and canrenoate potassium. As results, baseline patient characteristics were similar between the furosemide (n = 30) and the tolvaptan (n = 30) groups, with no significant difference in 5 day urine volume or fluid balance. Brain natriuretic peptide and body weight improvements were similar between groups. However, serum creatinine (Cr) level did not increase, and the incidence of worsening renal function was significantly lower in the tolvaptan group. Consequently, the Cr increase to gain 1000 mL urine was 2.5-fold lower in the tolvaptan group. Furthermore, the blood urea nitrogen (BUN)\/Cr ratio significantly decreased in the tolvaptan group, suggesting that renal perfusion was preserved, and urea reuptake and passive water reabsorption were suppressed following tolvaptan treatment. Although catecholamine improvements after treatment were not significantly different, plasma renin activity was enhanced in the furosemide group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>As compared with furosemide, tolvaptan in patients with acute heart failure is associated with comparable decongestion, better preservation of renal function and less activation of renin\u2013angiotensin system. (UMIN 000014134).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12088","type":"journal-article","created":{"date-parts":[[2016,3,31]],"date-time":"2016-03-31T18:50:21Z","timestamp":1459450221000},"page":"177-188","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["Randomized Pilot Trial Comparing Tolvaptan with Furosemide on Renal and Neurohumoral Effects in Acute Heart Failure"],"prefix":"10.1093","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2011-8204","authenticated-orcid":false,"given":"Kentaro","family":"Jujo","sequence":"first","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University , Tokyo ,","place":["Japan"]},{"name":"Department of Cardiology, Nishiarai Heart Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Saito","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nishiarai Heart Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nishiarai Heart Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuho","family":"Furuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nishiarai Heart Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nishiarai Heart Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nishiarai Heart Center Hospital , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aoyama Hospital, Tokyo Women's Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women's Medical University , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,3,31]]},"reference":[{"key":"2026012115141149800_ehf212088-bib-0001","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1056\/NEJMra021498","article-title":"Heart failure","volume":"348","author":"Jessup","year":"2003","journal-title":"N Engl J Med"},{"key":"2026012115141149800_ehf212088-bib-0002","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1161\/CIRCULATIONAHA.108.191259","article-title":"Heart disease and stroke statistics\u20142009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee","volume":"119","author":"Lloyd-Jones","year":"2009","journal-title":"Circulation"},{"key":"2026012115141149800_ehf212088-bib-0003","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1016\/S0140-6736(05)66621-4","article-title":"Heart failure","volume":"365","author":"McMurray","year":"2005","journal-title":"Lancet"},{"key":"2026012115141149800_ehf212088-bib-0004","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ahj.2004.08.005","article-title":"Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)","volume":"149","author":"Adams","year":"2005","journal-title":"Am Heart J"},{"key":"2026012115141149800_ehf212088-bib-0005","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2009.08.083","article-title":"Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score","volume":"55","author":"O'Connor","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0006","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1161\/CIRCHEARTFAILURE.109.885210","article-title":"Recent national trends in readmission rates after heart failure hospitalization","volume":"3","author":"Ross","year":"2010","journal-title":"Circ Heart Fail"},{"key":"2026012115141149800_ehf212088-bib-0007","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1093\/eurjhf\/hfq045","article-title":"Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine","volume":"12","author":"Gheorghiade","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026012115141149800_ehf212088-bib-0008","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2215\/CJN.03150509","article-title":"Cardiorenal syndrome in acute decompensated heart failure","volume":"4","author":"Sarraf","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012115141149800_ehf212088-bib-0009","doi-asserted-by":"crossref","first-page":"F1115","DOI":"10.1152\/ajprenal.00337.2002","article-title":"AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure","volume":"284","author":"Chen","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012115141149800_ehf212088-bib-0010","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"2026012115141149800_ehf212088-bib-0011","first-page":"169","article-title":"Tubuloglomerular feedback and the control of glomerular filtration rate","volume":"18","author":"Vallon","year":"2003","journal-title":"News Physiol Sci"},{"key":"2026012115141149800_ehf212088-bib-0012","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/0002-9149(87)90615-1","article-title":"Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics","volume":"60","author":"Kubo","year":"1987","journal-title":"Am J Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"2026012115141149800_ehf212088-bib-0014","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/293938","article-title":"Cardiorenal syndrome in acute heart failure syndromes","author":"Sarraf","year":"2011","journal-title":"Int J Nephrol"},{"key":"2026012115141149800_ehf212088-bib-0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jacc.2003.07.031","article-title":"Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure","volume":"43","author":"Forman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0016","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/eurjhf\/hfp169","article-title":"Acute kidney injury and outcomes in acute decompensated heart failure: evaluation of the RIFLE criteria in an acutely ill heart failure population","volume":"12","author":"Hata","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026012115141149800_ehf212088-bib-0017","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1536\/ihj.53.313","article-title":"Long-term prognostic impact after acute kidney injury in patients with acute heart failure","volume":"53","author":"Shirakabe","year":"2012","journal-title":"Int Heart J"},{"key":"2026012115141149800_ehf212088-bib-0018","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1253\/circj.CJ-12-0994","article-title":"Prognostic impact of acute kidney injury in patients with acute decompensated heart failure","volume":"77","author":"Shirakabe","year":"2013","journal-title":"Circ J"},{"key":"2026012115141149800_ehf212088-bib-0019","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ahj.2012.08.019","article-title":"Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure","volume":"164","author":"Shah","year":"2012","journal-title":"Am Heart J"},{"key":"2026012115141149800_ehf212088-bib-0020","doi-asserted-by":"crossref","first-page":"8B","DOI":"10.1016\/j.amjcard.2005.03.003","article-title":"Neurohormonal activation in congestive heart failure and the role of vasopressin","volume":"95","author":"Chatterjee","year":"2005","journal-title":"Am J Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0021","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"2026012115141149800_ehf212088-bib-0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","year":"1991","journal-title":"N Engl J Med"},{"key":"2026012115141149800_ehf212088-bib-0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"2026012115141149800_ehf212088-bib-0024","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"2026012115141149800_ehf212088-bib-0025","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"2026012115141149800_ehf212088-bib-0026","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026012115141149800_ehf212088-bib-0027","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026012115141149800_ehf212088-bib-0028","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"key":"2026012115141149800_ehf212088-bib-0029","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2026012115141149800_ehf212088-bib-0030","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"issue":"Suppl 1","key":"2026012115141149800_ehf212088-bib-0031","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/s10557-011-6349-x","article-title":"Phase III clinical pharmacology study of tolvaptan","volume":"25","author":"Inomata","year":"2011","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026012115141149800_ehf212088-bib-0032","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0033","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","article-title":"Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012115141149800_ehf212088-bib-0034","first-page":"154","article-title":"High furosemide dose has detrimental effects on survival of patients with stable heart failure","volume":"56","author":"Kapelios","year":"2015","journal-title":"Hellenic J Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0035","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","article-title":"A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction","volume":"17","author":"Udelson","year":"2011","journal-title":"J Card Fail"},{"key":"2026012115141149800_ehf212088-bib-0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"2026012115141149800_ehf212088-bib-0037","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1161\/CIRCHEARTFAILURE.113.000828","article-title":"Decongestive therapy and renal function in acute heart failure: time for a new approach?","volume":"7","author":"Goldsmith","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026012115141149800_ehf212088-bib-0038","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1113\/jphysiol.1993.sp019826","article-title":"Interrelation between baroreceptor and macula densa mechanisms in the control of renin secretion","volume":"469","author":"Scholz","year":"1993","journal-title":"J Physiol"},{"key":"2026012115141149800_ehf212088-bib-0039","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/j.1365-201X.2004.01329.x","article-title":"Cyclooxygenase-2 and the renal renin\u2013angiotensin system","volume":"181","author":"Harris","year":"2004","journal-title":"Acta Physiol Scand"},{"key":"2026012115141149800_ehf212088-bib-0040","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1001\/jama.2013.282190","article-title":"Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial","volume":"310","author":"Chen","year":"2013","journal-title":"JAMA"},{"key":"2026012115141149800_ehf212088-bib-0041","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacc.2011.01.052","article-title":"Interaction between loop diuretic-associated mortality and blood urea nitrogen concentration in chronic heart failure","volume":"58","author":"Testani","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0042","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00424-008-0612-4","article-title":"Essential role of vasopressin-regulated urea transport processes in the mammalian kidney","volume":"458","author":"Fenton","year":"2009","journal-title":"Pflugers Arch"},{"key":"2026012115141149800_ehf212088-bib-0043","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/CIRCHEARTFAILURE.108.770834","article-title":"Blood urea nitrogen and serum creatinine: not married in heart failure","volume":"1","author":"Schrier","year":"2008","journal-title":"Circ Heart Fail"},{"key":"2026012115141149800_ehf212088-bib-0044","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.amjcard.2010.04.024","article-title":"Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure","volume":"106","author":"Kazory","year":"2010","journal-title":"Am J Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0045","doi-asserted-by":"crossref","first-page":"F917","DOI":"10.1152\/ajprenal.00413.2010","article-title":"Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension?","volume":"299","author":"Bankir","year":"2010","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012115141149800_ehf212088-bib-0046","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade","year":"2007","journal-title":"Eur Heart J"},{"key":"2026012115141149800_ehf212088-bib-0047","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.amjcard.2008.09.091","article-title":"Relation of serum sodium level to long-term outcome after a first hospitalization for heart failure with preserved ejection fraction","volume":"103","author":"Rusinaru","year":"2009","journal-title":"Am J Cardiol"},{"key":"2026012115141149800_ehf212088-bib-0048","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000363721","article-title":"Renal functional reserve and renal recovery after acute kidney injury","volume":"127","author":"Sharma","year":"2014","journal-title":"Nephron Clin Pract"},{"key":"2026012115141149800_ehf212088-bib-0049","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cardfail.2015.05.007","article-title":"Carperitide is associated with increased in-hospital mortality in acute heart failure: a propensity score-matched analysis","volume":"21","author":"Matsue","year":"2015","journal-title":"J Card Fail"},{"key":"2026012115141149800_ehf212088-bib-0050","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1253\/circj.CJ-13-0187","article-title":"Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry)","volume":"77","author":"Sato","year":"2013","journal-title":"Circ J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12088","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12088","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12088","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/3\/3\/177\/66256609\/eschf_3_3_177.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/3\/3\/177\/66256609\/eschf_3_3_177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:19:14Z","timestamp":1769026754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/3\/3\/177\/8413145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,31]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,31]]},"published-print":{"date-parts":[[2016,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12088","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,9]]},"published":{"date-parts":[[2016,3,31]]},"assertion":[{"value":"2015-11-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-02-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}